Saint Michael's Medical Center | Research Department

Research site

(Unclaimed)

Location

111 Central Avenue, Newark, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

Ritonavir

Tenofovir

Lenacapavir

Elvitegravir

Rilpivirine

Tenofovir Alafenamide

Efavirenz

Tenofovir Disoproxil Fumarate

TAF

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 62 total trials

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS...

Enrolling

HIV-1-infection

Drug: Lenacapavir Injection

Drug: GS-3242 Injection

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only

Acute Myocardial Infarction

Combination Product: Placebo

Combination Product: Selatogrel

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting

HIV-1-Infection

Drug: Lepetegravir

Drug: Lepetegravir/Lenacapavir pacfosacil FDC

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: PTM ISL/LEN

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting

HIV-1-Infection

Drug: Antiretroviral Combinations

Drug: ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: Placebo to match B/F/TAF